Juvenile idiopathic arthritis is the most common autoimmune disease in childhood—the incidence among children under 16 is approximately 1 in 1,000. Early diagnosis and appropriate treatment remain a challenge. As part of a multidisciplinary approach, collaboration between primary care physicians and specialists in rheumatology—as well as other relevant disciplines when necessary—is crucial for achieving the best possible long-term outcomes. A wide range of disease-modifying medications (csDMARDs, bDMARDs, tsDMARDs) is now available as first-line therapy.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo RHEUMATOLOGIE
Related Topics
- Abatacept
- Arava
- Arthritis
- Autoimmune disease
- bDMARDs
- Biologics
- Canakinumab
- Childhood
- csDMARDs
- disease-modifying drugs
- Early detection
- Essential Medications
- Hydroxychloroquine
- Ilaris
- Infliximab
- interdisciplinary setting
- JAK-i
- jiA
- Juvenile idiopathic arthritis
- Leflunomide
- MTX
- Orencia
- Remicade
- Rheumatology
- Sulfasalazine
- targeted treatment
- tsDMARDs
- Uveitis
You May Also Like
- Juvenile Idiopathic Arthritis
Early Detection and Targeted Treatment in an Interdisciplinary Setting
- Disorders of the Gut-Brain Interaction
Rome V Criteria: What Has Changed, and What Has Remained the Same?
- Tourette Syndrome
What can be done to treat this tic disorder?
- Chronic Hepatitis B: Is a Cure in Sight?
Phase III Trial of Temporary Treatment with Bepirovirsen Was Successful
- Congenital Vascular Malformations
Personalized Treatment Before a Planned Pregnancy
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Clinically Suspected Arthralgias
“Watchful waiting” or intervention?
- Tumors of the Calcaneus